We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You can read more about our cookies before you choose.
Clinical Commissioning Policy: Rituximab for immunoglobulin G4 – related disease (IgG4 – RD)
This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission rituximab for patients with IgG4 – RD for a small number of highly selected patients.
